Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy
Clinical Feasibility of the ARCHITECT Applicator in High-dose-rate Cervical Cancer Brachytherapy
- Locally Advanced Cervical Cancer
- Uterine Carcinoma
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Erasmus Medical Center
- Enrolment target
- 25
- Started
- 22 July 2026
- Main results due
- December 2027
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Women only.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Locally advanced cervical cancer (FIGO 2018 stage 1B3-IVA) with indication for primary radiotherapy including brachytherapy * Written informed consent Exclusion Criteria: * Unable to give informed consent; * Tumour extension in the lower 2/3rd of the vagina; * Requiring a Geneva tandem with ovoids' size 13 mm in the first application for brachytherapy; * Known nylon allergy.
What this study is about
In the sponsor’s own words, from the registry.
This prospective, non-randomised, single centre, phase I trial assesses the clinical feasibility of the use of the patient-tailored ARCHITECT applicator in locally advanced cervical cancer brachytherapy.
Study sites(1)
Erasmus Medical Center
Rotterdam, Netherlands
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07435987. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me